Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma
Autor: | Masatoshi Ishigami, Teiji Kuzuya, Yoji Ishizu, Takashi Honda, Mitsuhiro Fujishiro, Tetsuya Ishikawa, Takanori Ito |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Drug-Related Side Effects and Adverse Reactions Kaplan-Meier Estimate Antibodies Monoclonal Humanized Disease-Free Survival Ramucirumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Albumins Internal medicine Humans Medicine Adverse effect Aged Neoplasm Staging Retrospective Studies Aged 80 and over business.industry Phenylurea Compounds Incidence (epidemiology) Liver Neoplasms Bilirubin Retrospective cohort study General Medicine Middle Aged medicine.disease digestive system diseases chemistry Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Hepatocellular carcinoma Quinolines Female alpha-Fetoproteins business Lenvatinib Alpha-fetoprotein |
Zdroj: | Anticancer Research. 40:2089-2093 |
ISSN: | 1791-7530 0250-7005 |
Popis: | Background/aim The outcomes of ramucirumab after lenvatinib failure for hepatocellular carcinoma (HCC) patients with alpha fetoprotein (AFP) levels of ≥400 ng/ml are unknown. Patients and methods Of 12 patients treated with ramucirumab after lenvatinib failure, 10 patients were enrolled in this retrospective study. Results The disease control rate of 80% at 6 weeks and the median time to progression of 3.1 months were the same by both the Response Evaluation Criteria in Solid Tumors (RECIST) and the modified RECIST. AFP reduction was seen in 5 patients at 2 weeks and in 3 patients at 6 weeks. The incidence of grade 3 adverse events was low at 10%. The albumin-bilirubin scores within 6 weeks did not worsen. Conclusion Ramucirumab might have potential therapeutic efficacy and safety in advanced HCC patients after lenvatinib failure. Further studies are needed to confirm the outcomes of ramucirumab after lenvatinib failure. |
Databáze: | OpenAIRE |
Externí odkaz: |